| Application no. and date | 20807558.0 (espacenet) (Federated) (European Patent Register), 20201020 | | Patent/reg. no. and date | DK/EP 4048278, 20231101 | | Publication date | 20220831 | | Priority no. and date | US 201962924028 P, 20191021 | | EP pub. no. and date |
EP 4048278 20220831 | | Effective date | | | Applicant/owner | Celgene Corporation, 86 Morris Avenue
Summit, NJ 07901, US | | Applicant ref. no. | P83336DK01 | | Inventor | ANTON, Maria Soraya, Carrancio, c/o Signal Pharmaceuticals, LLC 10300 Campus
Point Drive, Suite 100
San Diego, CA 92121, US,
BUCHHOLZ, Tonia J., c/o Celgene Corporation 1500 Owens Street, Suite
600
San Francisco, CA 94185, US,
KASIBHATLA, Shailaja, c/o Signal Pharmaceuticals, LLC 10300 Campus
Point Drive, Suite 100
San Diego, CA 92121, US,
LOPEZ-GIRONA, Antonia, c/o Signal Pharmaceuticals, LLC 10300 Campus
Point Drive, Suite 100
San Diego, CA 92121, US,
NARLA, Rama, Krishna, c/o Signal Pharmaceuticals, LLC 10300 Campus
Point Drive, Suite 100
San Diego, CA 92121, US,
POURDEHNAD, Michael, c/o Celgene Corporation 1500 Owens Street, Suite
600
San Francisco, CA 94185, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/5377 (2006.01) , A61P 35/00 (2006.01) | | Title | FREMGANGSMÅDER TIL BEHANDLING AF HÆMATOLOGISKE MALIGNITETER UNDER ANVENDELSE AF 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUOR-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLIN-1,3-DION | | Int. application no. | US2020056408 | | Int. publication no. | WO2021080935 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
